 Steven Bines
Concepts (123)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Melanoma | 5 | 2017 | 60 | 1.440 |
Why?
| | Sentinel Lymph Node Biopsy | 2 | 2017 | 20 | 0.630 |
Why?
| | Aptitude Tests | 1 | 2013 | 2 | 0.620 |
Why?
| | General Surgery | 2 | 2013 | 56 | 0.600 |
Why?
| | Genetic Therapy | 2 | 2013 | 89 | 0.580 |
Why?
| | Ileal Neoplasms | 1 | 2011 | 2 | 0.540 |
Why?
| | Skin Neoplasms | 2 | 2013 | 141 | 0.510 |
Why?
| | Clinical Competence | 1 | 2013 | 245 | 0.500 |
Why?
| | Herpesvirus 1, Human | 1 | 2010 | 3 | 0.490 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2010 | 31 | 0.490 |
Why?
| | Genetic Vectors | 1 | 2010 | 66 | 0.470 |
Why?
| | Laparoscopy | 1 | 2011 | 172 | 0.460 |
Why?
| | Rosaniline Dyes | 1 | 2008 | 3 | 0.440 |
Why?
| | Radioisotopes | 1 | 2008 | 15 | 0.440 |
Why?
| | Neoplasm Invasiveness | 1 | 2008 | 100 | 0.420 |
Why?
| | Neoplasm Staging | 2 | 2017 | 479 | 0.420 |
Why?
| | Breast Neoplasms | 1 | 2008 | 404 | 0.310 |
Why?
| | Immunotherapy | 2 | 2013 | 67 | 0.290 |
Why?
| | Cancer Vaccines | 2 | 2012 | 19 | 0.260 |
Why?
| | Carcinoma, Renal Cell | 2 | 2012 | 75 | 0.240 |
Why?
| | Opioid-Related Disorders | 1 | 2017 | 20 | 0.200 |
Why?
| | Watchful Waiting | 1 | 2017 | 9 | 0.200 |
Why?
| | Lymph Node Excision | 1 | 2017 | 37 | 0.200 |
Why?
| | Clinical Clerkship | 2 | 2013 | 27 | 0.190 |
Why?
| | Humans | 13 | 2017 | 26729 | 0.190 |
Why?
| | Analgesics, Opioid | 1 | 2017 | 118 | 0.180 |
Why?
| | Pain Management | 1 | 2017 | 116 | 0.180 |
Why?
| | Lymph Nodes | 2 | 2017 | 81 | 0.170 |
Why?
| | Chronic Disease | 1 | 2017 | 485 | 0.170 |
Why?
| | Retrospective Studies | 3 | 2017 | 2780 | 0.170 |
Why?
| | Gastrostomy | 1 | 2015 | 10 | 0.170 |
Why?
| | Gastroscopy | 1 | 2015 | 9 | 0.170 |
Why?
| | Mental Disorders | 1 | 2017 | 192 | 0.160 |
Why?
| | Patient Safety | 1 | 2015 | 48 | 0.160 |
Why?
| | Ambulatory Surgical Procedures | 1 | 2015 | 73 | 0.160 |
Why?
| | Animals, Laboratory | 1 | 2013 | 3 | 0.150 |
Why?
| | Adult | 5 | 2017 | 8754 | 0.150 |
Why?
| | Hypopigmentation | 1 | 2013 | 1 | 0.150 |
Why?
| | Vitiligo | 1 | 2013 | 2 | 0.150 |
Why?
| | Students, Medical | 1 | 2013 | 39 | 0.150 |
Why?
| | Mutant Proteins | 1 | 2013 | 9 | 0.150 |
Why?
| | HSP70 Heat-Shock Proteins | 1 | 2013 | 8 | 0.150 |
Why?
| | Head and Neck Neoplasms | 1 | 2015 | 132 | 0.150 |
Why?
| | Education, Medical | 1 | 2013 | 37 | 0.150 |
Why?
| | Autoimmunity | 1 | 2013 | 23 | 0.150 |
Why?
| | Animals | 6 | 2013 | 4851 | 0.150 |
Why?
| | Molecular Targeted Therapy | 1 | 2013 | 38 | 0.150 |
Why?
| | Immunotherapy, Active | 1 | 2012 | 4 | 0.140 |
Why?
| | Laparoscopes | 1 | 2011 | 3 | 0.130 |
Why?
| | Middle Aged | 5 | 2017 | 10097 | 0.130 |
Why?
| | Biopsy, Needle | 1 | 2011 | 114 | 0.130 |
Why?
| | Defective Viruses | 1 | 2010 | 1 | 0.120 |
Why?
| | Cytopathogenic Effect, Viral | 1 | 2010 | 3 | 0.120 |
Why?
| | Kidney Neoplasms | 1 | 2012 | 106 | 0.120 |
Why?
| | Injections, Intralesional | 1 | 2010 | 32 | 0.120 |
Why?
| | Clinical Protocols | 1 | 2010 | 62 | 0.120 |
Why?
| | Antineoplastic Agents | 1 | 2013 | 296 | 0.120 |
Why?
| | Virus Replication | 1 | 2010 | 90 | 0.120 |
Why?
| | Immunohistochemistry | 1 | 2011 | 478 | 0.120 |
Why?
| | Prostatic Neoplasms | 1 | 2010 | 132 | 0.110 |
Why?
| | Prospective Studies | 2 | 2013 | 1590 | 0.110 |
Why?
| | Coloring Agents | 1 | 2008 | 16 | 0.110 |
Why?
| | Mice | 2 | 2013 | 1664 | 0.110 |
Why?
| | Drug Hypersensitivity | 1 | 2008 | 18 | 0.110 |
Why?
| | Colorectal Neoplasms | 1 | 2010 | 107 | 0.110 |
Why?
| | Treatment Outcome | 3 | 2015 | 3364 | 0.110 |
Why?
| | Adenocarcinoma | 1 | 2010 | 227 | 0.110 |
Why?
| | Research Design | 1 | 2010 | 188 | 0.110 |
Why?
| | Patient Selection | 1 | 2010 | 235 | 0.110 |
Why?
| | Chi-Square Distribution | 1 | 2008 | 178 | 0.100 |
Why?
| | Linear Models | 1 | 2008 | 257 | 0.100 |
Why?
| | Analysis of Variance | 1 | 2008 | 366 | 0.100 |
Why?
| | Minimally Invasive Surgical Procedures | 1 | 2011 | 262 | 0.100 |
Why?
| | Male | 6 | 2017 | 15601 | 0.100 |
Why?
| | Sensitivity and Specificity | 1 | 2008 | 585 | 0.090 |
Why?
| | Aged | 4 | 2017 | 8906 | 0.090 |
Why?
| | Tomography, X-Ray Computed | 1 | 2011 | 823 | 0.090 |
Why?
| | Follow-Up Studies | 1 | 2011 | 1872 | 0.090 |
Why?
| | Risk Assessment | 1 | 2008 | 719 | 0.080 |
Why?
| | Female | 5 | 2017 | 15965 | 0.080 |
Why?
| | Cohort Studies | 1 | 2008 | 1650 | 0.070 |
Why?
| | Young Adult | 2 | 2017 | 1937 | 0.060 |
Why?
| | Clinical Trials as Topic | 2 | 2012 | 370 | 0.060 |
Why?
| | Postoperative Complications | 2 | 2017 | 978 | 0.050 |
Why?
| | Pain Clinics | 1 | 2017 | 6 | 0.050 |
Why?
| | Intention to Treat Analysis | 1 | 2017 | 6 | 0.050 |
Why?
| | Lymphatic Metastasis | 1 | 2017 | 99 | 0.050 |
Why?
| | Lymphedema | 1 | 2017 | 21 | 0.050 |
Why?
| | Academic Medical Centers | 1 | 2017 | 135 | 0.050 |
Why?
| | Disease-Free Survival | 1 | 2017 | 230 | 0.050 |
Why?
| | Palliative Care | 1 | 2017 | 104 | 0.050 |
Why?
| | Survival Analysis | 1 | 2017 | 372 | 0.050 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2017 | 510 | 0.050 |
Why?
| | Aged, 80 and over | 2 | 2017 | 4537 | 0.050 |
Why?
| | Proportional Hazards Models | 1 | 2017 | 336 | 0.040 |
Why?
| | Ultrasonography | 1 | 2017 | 186 | 0.040 |
Why?
| | Prognosis | 1 | 2017 | 920 | 0.040 |
Why?
| | Antigens | 1 | 2013 | 30 | 0.040 |
Why?
| | Antigen-Presenting Cells | 1 | 2013 | 18 | 0.040 |
Why?
| | Medical Oncology | 1 | 2013 | 37 | 0.040 |
Why?
| | Vaccination | 1 | 2013 | 32 | 0.040 |
Why?
| | Neoplasm Metastasis | 1 | 2013 | 138 | 0.040 |
Why?
| | Transfection | 1 | 2013 | 150 | 0.040 |
Why?
| | Forecasting | 1 | 2013 | 128 | 0.040 |
Why?
| | Dendritic Cells | 1 | 2013 | 62 | 0.040 |
Why?
| | Transcription, Genetic | 1 | 2013 | 124 | 0.040 |
Why?
| | Skin | 1 | 2013 | 128 | 0.030 |
Why?
| | Anxiety | 1 | 2013 | 136 | 0.030 |
Why?
| | Disease Management | 1 | 2013 | 123 | 0.030 |
Why?
| | Models, Immunological | 1 | 2012 | 8 | 0.030 |
Why?
| | Peptides | 1 | 2013 | 113 | 0.030 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2012 | 37 | 0.030 |
Why?
| | Lymphocyte Activation | 1 | 2013 | 214 | 0.030 |
Why?
| | Evidence-Based Medicine | 1 | 2013 | 215 | 0.030 |
Why?
| | Phenotype | 1 | 2013 | 331 | 0.030 |
Why?
| | T-Lymphocytes | 1 | 2013 | 228 | 0.030 |
Why?
| | Societies, Medical | 1 | 2013 | 183 | 0.030 |
Why?
| | Mice, Inbred C57BL | 1 | 2013 | 476 | 0.030 |
Why?
| | Stress, Psychological | 1 | 2013 | 254 | 0.030 |
Why?
| | Inflammation | 1 | 2013 | 303 | 0.030 |
Why?
| | Models, Animal | 1 | 2010 | 149 | 0.030 |
Why?
| | Disease Progression | 1 | 2013 | 759 | 0.030 |
Why?
| | United States | 1 | 2013 | 2104 | 0.020 |
Why?
|
|
Bines's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|